<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145663</url>
  </required_header>
  <id_info>
    <org_study_id>HUSBS2013</org_study_id>
    <secondary_id>MNEURT ISCHEMIC STROKE 813</secondary_id>
    <nct_id>NCT02145663</nct_id>
  </id_info>
  <brief_title>Helsinki Ultra-acute Stroke Biomarker Study</brief_title>
  <official_title>Helsinki Ultra-acute Stroke Biomarker Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HUS area Prehospital Emergency Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish diagnostic and predictive biomarkers for patients with
      suspected acute stroke, that are transported by EMS as candidates for thrombolytic
      treatment. The study focuses on the ultra acute phase, &lt;4.5 hours from symptom onset,
      including the prehospital setting. Analyses will include known biomarkers (e.g. GFAP, NR2
      peptide) and a discovery phase for novel markers. Patient outcome will be evaluated at 3
      month using the modified Rankin Scale (mRS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Diagnostic accuracy of biomarkers for identifying ischemic stroke, transient ischemic attack, intracerebral hemorrhage and stroke mimics.</measure>
    <time_frame>90 days +/- 5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive accuracy of biomarkers for identifying patients not responding to thrombolytic treatment.</measure>
    <time_frame>90 days +/- 5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive accuracy of biomarkers for identifying patients facing hemorrhagic complications of thrombolytic treatment</measure>
    <time_frame>90 days +/- 5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive accuracy of biomarkers for predicting outcome</measure>
    <time_frame>90 days +/- 5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Stroke</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human Serum and Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected acute stroke, being transported by emergency medical services
        (EMS) to a tertiary hospital stroke center, as candidates for thrombolytic treatment of
        acute ischemic stroke.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute stroke suspected by EMS personnel

          -  Transport to tertiary hospital as possible candidate for thrombolytic treatment of
             ischemic stroke

          -  Age â‰¥18

          -  Successful prehospital blood sampling by EMS personnel

        Exclusion Criteria:

          -  Unsuccessful prehospital blood sampling by EMS personnel
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perttu Lindsberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perttu Lindsberg, MD, PhD</last_name>
    <phone>400634395</phone>
    <phone_ext>+358</phone_ext>
    <email>perttu.lindsberg@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Perttu Lindsberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://research.med.helsinki.fi/neuro/lindsberg/default.html</url>
    <description>Group internet page</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>May 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Perttu Lindsberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
